Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Clinical Oncology

• Publication date

  2004-03-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2004.06.037PMID 15020604
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.

  2003cited by this paper
• Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

  2003cited by this paper
• Cancer Statistics, 2003

  2003cited by this paper
• Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival.

  2001cited by this paper
• A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma

  2000cited by this paper
• Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

  2000cited by this paper
• Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group.

  2000cited by this paper
• Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone.

  2000cited by this paper
• Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

  1999cited by this paper
• Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.

  1999cited by this paper
• Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer.

  1999cited by this paper
• Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

  1999cited by this paper
• Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer.

  1998cited by this paper
• Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal.

  1997cited by this paper
• Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma

  1997cited by this paper
• Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer.

  1995cited by this paper
• The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer

  1995cited by this paper
• Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.

  1995cited by this paper
• Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment.

  1995cited by this paper
• Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer.

  1994cited by this paper
• Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer.

  1993cited by this paper
• Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.

  1993cited by this paper
• Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer.

  1990cited by this paper
• High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects.

  1989cited by this paper
• Objective responses to ketoconazole therapy in patients with relapsed progressive prostatic cancer.

  1986cited by this paper
• Ketoconazole: a novel and rapid treatment for advanced prostatic cancer.

  1983cited by this paper
• Analysis of survival by tumor response.

  1983cited by this paper
• Discrete sequential boundaries for clinical trials

  1983cited by this paper
• Allocation of patients to treatment in clinical trials.

  1979cited by this paper
• Allocation of patients to treatment in clinical trials.

  1979cited by this paper
• Regression Models and Life-Tables

  1972cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper
• Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.

  1941cited by this paper

• Targeted inhibition of FBXL2 confers susceptibility of HER2-negative breast cancer to trastuzumab deruxtecan

  2026cites this paper
• 2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-resistant prostate cancer (Update).

  2025cites this paper
• Optimizing Radiation Therapy for Localized Prostate Cancer: Exploring Synergies With Androgen Deprivation Therapy and Novel Systemic Agents.

  2025cites this paper
• Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology.

  2025cites this paper
• Targeting androgen biosynthesis in prostate cancer: implications on endocrine physiology

  2024cites this paper
• Survival by first‐line therapy and prognostic group among men with metastatic castration‐resistant prostate cancer

  2024cites this paper
• Updates in the Treatment of Non-Metastatic Castrate-Resistant Prostate Cancer: The Benefit of Second-Generation Androgen Receptor Antagonists

  2023cites this paper
• Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology.

  2023cites this paper
• CÂNCER DE PRÓSTATA

  2022cites this paper
• The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: Randomized trial

  2022cites this paper
• 2022 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).

  2022cites this paper
• Repurposing antifungal drugs for cancer therapy

  2022cites this paper
• Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells

  2022cites this paper
• NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ® ) Prostate Cancer Early Detection Version 1 . 2022 —

  2022cites this paper
• Testosterone analysis in prostate cancer patients.

  2022cites this paper
• Repurposing ketoconazole as an exosome directed adjunct to sunitinib in treating renal cell carcinoma

  2021cites this paper
• 2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).

  2021cites this paper
• Androgen receptor signalling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration sensitive prostate cancer.

  2021cites this paper
• Current Treatment Modalities Targeting Tumor Microenvironment in Castration-Resistant Prostate Cancer.

  2021cites this paper
• Molecular Basis of Prostate Cancer and Natural Products as Potential Chemotherapeutic and Chemopreventive Agents

  2021cites this paper
• PSA response to antiandrogen withdrawal: a systematic review and meta-analysis

  2021cites this paper
• Prevention and Therapy of Prostate Cancer: An Update on Alternatives for Treatment and Future Perspectives

  2020cites this paper
• Emerging and investigational targeted chemotherapy and immunotherapy agents for metastatic brain tumors

  2020cites this paper
• Recent developments in the treatment of non-metastatic castration resistant prostate cancer.

  2020cites this paper
• Imidazole Antifungals: A Review of Their Action Mechanisms on Cancerous Cells

  2020cites this paper
• A castration-resistant terminal prostate cancer patient ’ s survival prolonged after practicing Falun Gong

  2020cites this paper
• Treatment gains from the “sandwich method” of abiraterone acetate for men with metastatic prostate cancer: a case report and sharing of our experience

  2020cites this paper
• Impact of antiandrogen withdrawal syndrome in castration‐resistant prostate cancer patients treated with abiraterone or enzalutamide

  2020cites this paper
• The Prostate

  2020cites this paper
• Abiraterone acetate treatment in patients with castration-resistant prostate cancer with visceral metastases: a real-world experience

  2019cites this paper
• Case Report: A castration-resistant terminal prostate cancer patient’s survival prolonged after practicing Falun Gong

  2019cites this paper
• Ketoconazole exacerbates mitophagy to induce apoptosis by downregulating cyclooxygenase-2 in hepatocellular carcinoma.

  2019cites this paper
• Management of advanced prostate cancer: A systematic review of existing guidelines and recommendations.

  2019cites this paper
• Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

  2019cites this paper
• Repurposed Drugs for Prostate Cancer.

  2019cites this paper
• Analyse protéomique des réseaux de signalisation du récepteur aux androgènes modulés par l'Enzalutamide dans le cancer de la prostate résistant à la castration

  2019cites this paper
• 2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guidelines for the management of castration-resistant prostate cancer (CRPC).

  2019cites this paper
• Treatment of Advanced Prostate Cancer.

  2019cites this paper
• Therapies Targeted to Androgen Receptor Signaling Axis in Prostate Cancer: Progress, Challenges, and Hope

  2019cites this paper
• Androgen Decline and Survival During Docetaxel Therapy in metastatic Castration Resistant Prostate Cancer (mCRPC)

  2019cites this paper
• Optimizing the Treatment Options for Metastatic Castration Resistant Prostate Cancer in a Resource Poor Setting: A Single Centre Experience

  2019cites this paper
• The role of ketoconazole in current prostate cancer care

  2018cites this paper
• Management of nonmetastatic castration-resistant prostate cancer

  2018cites this paper
• Prognostic and Predictive Factors for Anti-androgen Withdrawal in Castration-resistant Prostate Cancer

  2018cites this paper
• Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study

  2018cites this paper
• Clinical Results of Secondary Hormonal Treatment

  2018cites this paper
• Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

  2018cites this paper
• Adrenal Androgen in Prostate Cancer

  2018cites this paper
• Hormonal therapy and overall management of prostate cancer

  2018influential citation
• Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review

  2018cites this paper
• Role of the androgen signaling axis in genitourinary malignancies.

  2018influential citation
• Alternative Antiandrogen Therapy for CRPC

  2018cites this paper
• Incidence of fatigue and low-dose corticosteroid use in prostate cancer patients receiving systemic treatment: a meta-analysis of randomized controlled trials

  2018cites this paper
• Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials

  2018cites this paper
• Metastatic prostate cancer remains incurable, why?

  2018cites this paper
• Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer

  2017cites this paper
• Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion.

  2017cites this paper
• Early use of chemotherapy in metastatic prostate cancer.

  2017cites this paper
• Investigating aberrant signalling in enzalutamide-resistant prostate cancer

  2017cites this paper
• Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment

  2017cites this paper
• Enzalutamide in the Treatment of Patients with Metastatic Castrate-Resistant Prostate Cancer

  2017cites this paper
• Estimating the healthcare costs of treating prostate cancer in Australia: A Markov modelling analysis.

  2017cites this paper
• Characterization of a novel androgen receptor (AR) coregulator RIPK1 and related chemicals that suppress AR-mediated prostate cancer growth via peptide and chemical screening

  2017cites this paper
• Papaverine selectively inhibits human prostate cancer cell (PC-3) growth by inducing mitochondrial mediated apoptosis, cell cycle arrest and downregulation of NF-κB/PI3K/Akt signalling pathway.

  2017cites this paper
• Korean Treatment Guidelines for Metastatic Prostate Cancer Developed by the Korean Association for Clinical Oncology

  2017cites this paper
• Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets.

  2017cites this paper
• Semaphorin 3C in prostate cancer tumourigenesis

  2017cites this paper
• The role of CYP17A1 in prostate cancer development: structure, function, mechanism of action, genetic variations and its inhibition.

  2017cites this paper
• Bone Metastases from Prostate Cancer: Hormonal Therapy

  2017cites this paper
• valuation of efficacy of buserelin plus nilutamide in exican Male patients with advanced prostate cancer

  2016cites this paper
• Novel functionalized 5-(phenoxymethyl)-1,3-dioxane analogs exhibiting cytochrome P450 inhibition: a patent evaluation WO2015048311 (A1)

  2016cites this paper
• Contemporary agents in the management of metastatic castration-resistant prostate cancer.

  2016cites this paper
• The anti-cancerous activity of recombinant trichosanthin on prostate cancer cell PC3

  2016cites this paper
• Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence.

  2016cites this paper
• Role of corticosteroids in prostate cancer progression: implications for treatment strategy in metastatic castration-resistant patients

  2016cites this paper
• Abiraterone for the Treatment of mCRPC

  2016cites this paper
• Title Impact of skeletal-related events on survival in patients with metastatic prostate cancer prescribed androgen deprivation therapy

  2016cites this paper
• Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review.

  2016cites this paper
• Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer

  2016cites this paper
• Trial Level Analysis of Prostate-Specific Antigen-Related Versus Unrelated Endpoints in Phase III Trials of First-Line and Second-Line Medical Treatments of Patients With Metastatic Castration-Resistant Prostate Cancer.

  2016cites this paper
• Emerging mutations and functional changes of androgen receptor associated with treatment resistance in prostate cancer

  2016cites this paper
• NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ® ) Prostate Cancer Early Detection

  2016cites this paper
• Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials.

  2016cites this paper
• Is computed tomography a necessary part of a metastatic evaluation for castration‐resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database

  2016influential citation
• Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance).

  2016cites this paper
• Evaluation of efficacy of buserelin plus nilutamide in Mexican Male patients with advanced prostate cancer

  2016cites this paper
• Second-Line Hormonal for Castrate-Resistant Prostate Cancer

  2016cites this paper
• Targeting of Steroid Hormone Receptor Function in Breast and Prostate Cancer

  2016cites this paper
• Economic modelling of healthcare services for prostate cancer

  2016cites this paper
• Chapter 6 Plumbagin and Prostate Cancer Therapy

  2016cites this paper
• Prostate cancer

  2016cites this paper
• Targeting persistent androgen receptor signaling in castration-resistant prostate cancer

  2016cites this paper
• Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer

  2015cites this paper
• A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer.

  2015cites this paper
• Singapore Cancer Network (SCAN) Guidelines for the Management of Advanced Castrate-Resistant Prostate Cancer.

  2015cites this paper
• Prostate Cancer Early Detection, Version 2.2015

  2015cites this paper
• Is there an antiandrogen withdrawal syndrome with enzalutamide?

  2015cites this paper
• Clinical outcomes of helical tomotherapy for super-elderly patients with localized and locally advanced prostate cancer: comparison with patients under 80 years of age

  2015cites this paper
• Enzalutamide: targeting the androgen signalling pathway in metastatic castration‐resistant prostate cancer

  2015cites this paper
• Management of advanced prostate cancer.

  2015cites this paper